Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Compass Pathways Q2 EPS $(0.50) Beats $(0.61) Estimate

Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.61) by 18.03 percent. This is a 13.64 percent decrease over losses of $(0.44) per share from
byBenzinga Newsdesk
August 4, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.61) by 18.03 percent. This is a 13.64 percent decrease over losses of $(0.44) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Sana Biotechnology Announces Publication Of Preclinical Diabetes Data In Cell Stem Cell Demonstrating Insulin Independence Following Transplantation Of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression In A Diabetic NHP

By Benzinga Newsdesk
February 13, 5:43 PM
Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression

SANA